Webinar review: Patient-Derived Xenografts on Humanized Mice

Webinar review: Patient-Derived Xenografts on Humanized Mice Dr. Jens Hoffmann of EPO presented a webinar highlighting new data on preclinical immuno-oncology research using humanized models. The growth in immuno-oncology (IO) research has created a need for more relevant models. The IO field includes many types of drugs, including:
  • genetically engineered immune cells such as CAR-T cells
  • various antibody-based therapies such as antibody-drug conjugates (ADCs) and bi-specific T cell engagers (BITEs)
  • oncolytic viruses and bacteria
Relevant in vivo models are needed to study all of these IO modes.

Current Options for Immuno-Oncology Models

Standard xenograft models, in which a human tumor is transplanted into an immunodeficient host, have limited utility for IO studies, as the appropriate immune cells are not present in the host. The current models of choice for IO research include:

Related InsightLearn more about preclinical immuno-oncology animal models and Read the Taconic Biosciences' Insight:
EPO has significant experience in syngeneic models, with a large panel of established tumor cell lines characterized for response to checkpoint inhibitors. They are now evaluating combination therapies (immune therapy + radiation) in these syngeneic models, including evaluating the immune cell infiltration into tumors after radiation treatment.

Webinar review: patient-derived Xenografts on Humanized Mice

Humanized Immune System Mice in IO

Dr. Hoffmann described use of both primary types of humanized immune system mice, those engrafted with human PBMCs and those engrafted with human CD34+ hematopoietic stem cells (HSCs). The PBMC model (huPBMC-NOG) is well-established and quite useful, but the study window is limited as the mice eventually develop graft versus host disease. The HSC model (huNOG) takes longer to get sufficient human cell engraftment and differentiation, but has the advantage of a longer useable study window.

EPO has measured stable engraftment of human immune cells up to 254 days post-engraftment in the HSC model. EPO has compared both the NOG and NOG-EXL models in the HSC engraftment model and saw, as reported by others, that overall engraftment levels were higher in the NOG-EXL. They also saw higher engraftment of T, B, NK and CD14+ monocytes in the NOG-EXL as compared to the NOG.

Preclinical Modeling of Human NK Cells

For studies requiring human NK cells, Dr. Hoffmann explained that the recently developed hIL-15 NOG mouse may be more suitable than the base NOG mouse. Following engraftment of human PBMCs, the hIL-15 NOG mice had higher engraftment of T cells compared to NOG mice, and also showed significant numbers of NK cells, which do not develop appreciably in NOG mice.

The huPBMC model is appropriate for study of the many types of IO therapies, including:

  • Bi-specific T cell engager antibodies (BITEs), which target a tumor antigen and recruit cytotoxic T cells
  • Checkpoint inhibitors
  • Oncolytic viruses
Dr. Hoffmann discussed a number of studies performed by EPO in which patient-derived tumors were engrafted on NOG mice which had also been humanized with HSCs. Some tumor types grew equally well in mice with and without HSCs, whereas the growth of other tumors was slowed in HSC-engrafted mice compared to non-humanized mice. In some cases, this was a donor effect, in that the growth characteristics of the same tumor varied between mice humanized with different donor HSCs.

Dr. Hoffmann showed validation data demonstrating efficacy of checkpoint inhibitor therapeutics against PDX in HSC-engrafted mice. He did caution that, because of donor-to-donor variability in both tumor growth and response to immunotherapies, it is important to use multiple HSC donors in each experiment.

Preclinical Immuno-Oncology Case Study

The webinar included an interesting case study involving a head-and-neck tumor. EPO studied this tumor in several contexts: in PBMC-engrafted mice, both with three unrelated donors as well as with autologous PBMCs from the cancer patient, and with three unrelated donors in the HSC-engrafted model.

In the PBMC model, the tumor grew similarly in mice humanized with the patient's autologous PBMCs and from two of the three unrelated donors, but the tumor grew much faster in the mice engrafted with one particular donor's PBMCs which happened to be well HLA-matched to the tumor.

The checkpoint inhibitor nivolumab showed good efficacy in mice from that latter donor. The head-and-neck tumor growth varied also in the HSC model across different donors, and similarly checkpoint inhibitor efficacy against the tumor also varied by donor.

Dr. Hoffmann indicated that the variability in tumor growth and in drug efficacy across different immune cell donors may be a window into understanding drug mechanisms of action and may even help tease out why some patients respond well to these new therapies while others show no response.

Share this Insight